Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at...
April 17 2018 - 12:00PM
Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that new
preclinical data supporting the development of microbiome
therapeutics for immuno-oncology (leveraging gut microbiota to
impact tumor immunotherapy)1 will be presented today by Sceneay et
al in the late breaking poster session at the 2018 American
Association for Cancer Research Annual Meeting (AACR) in Chicago.
The data presented provide new insights on the potential mechanism
by which Seres’ microbiome therapies could improve the outcomes of
cancer patients treated with immune checkpoint inhibitors.
“The data presented at AACR provide important new models and
mechanistic insights that inform our planned development efforts to
evaluate the ability of microbiome therapy to augment immune
checkpoint inhibitors,” said David Cook, Ph.D., Chief
Scientific Officer and Executive Vice President of Research at
Seres. “The insights described in this presentation will guide the
continued development of SER-401, which we expect to enter clinical
development later this year. Our objective is to use our microbiome
therapeutic approach to improve the efficacy of immunotherapy in
patients with life-threatening cancers.”
Seres presented results from preclinical studies designed to
evaluate the impact of various consortia of bacterial species on
the anti-tumor immune response in murine models following treatment
with an anti-PD-1 checkpoint inhibitor. Results demonstrated that
both germ-free mice lacking a microbiome and antibiotics-treated
mice with a dysbiotic microbiome, failed to mount an effective
anti-tumor response following treatment with an anti-PD-1
checkpoint inhibitor. The response to anti-PD-1 was restored in
germ-free as well as antibiotics-treated mice by introducing a
diverse microbiome, and was driven by increased entry of
tumor-infiltrating lymphocytes into the tumor; specifically, CD8+ T
effector cells. Current pre-clinical efforts are focused on
optimizing specific microbiome compositions based on functional and
phylogenetic information to inform the development of therapeutic
candidates.
Seres is developing SER-401, a preclinical stage oral microbiome
therapy comprising a consortium of live bacteria to improve the
efficacy and safety of immunotherapy. Through a collaboration with
The University of Texas MD Anderson Cancer Center and the Parker
Institute for Cancer Immunotherapy, Seres plans to initiate a
clinical study in patients with advanced metastatic melanoma later
this year. In a 2017 study published in Science, the MD Anderson
research team, led by Dr. Jennifer Wargo, described a microbiome
signature associated with response to checkpoint inhibitor therapy.
A planned clinical trial will evaluate the impact of an anti-PD-1
checkpoint inhibitor with adjunctive microbiome therapy on patient
outcomes.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics
platform company developing a novel class of biological drugs that
are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the natural state of bacterial
diversity and function is imbalanced. Seres’ lead program, SER-109,
has obtained Breakthrough Therapy and Orphan Drug designations from
the U.S. Food and Drug Administration and is in Phase 3
development for multiply
recurrent C. difficile infection. Seres’ clinical
candidate SER-287 has successfully completed a Phase 1b study in
patients with mild-to-moderate Ulcerative Colitis. Seres is also
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit
www.serestherapeutics.com. Follow us on Twitter @SeresTx.
References
1. Sceneay, Jaclyn et. al., Leveraging gut microbiota to impact
tumor immunotherapy. Poster. American Association for Cancer
Research Annual Meeting 2018.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417005622/en/
Seres TherapeuticsCarlo Tanzi, Ph.D., 617-203-3467Vice
President, Investor Relations and Corporate
Communicationsctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2023 to Apr 2024